- I pazienti con psoriasi presentano un’alterazione endoteliale direttamente correlata con l’attività della malattia cutanea e con i livelli circolanti dei marcatori dell’infiammazione sistemica.
- Il presente studio è un trial randomizzato in aperto sulla terapia ipolipemizzante per ridurre l’infiammazione endoteliale nei pazienti con psoriasi.
Abstract
In psoriasis, immune systemic activation and cardiometabolic abnormalities, including dyslipidemia, play a role in promoting impaired endothelial health and increased cardiovascular (CV) risk ( Greb et al., 2016). Patients with psoriasis have elevated brachial vein endothelial proinflammatory transcript expression (impaired vascular endothelial health), with the degree of impairment directly correlated with skin activity and circulating biomarkers of systemic inflammation ( Garshick et al., 2019). In psoriasis, TNF and IL-17A synergism promote inflammasome (IL-1β) signaling and downstream IL-6 production (driver of CRP) ( Verma et al., 2021), which associates with vascular endothelial inflammatory transcript expression, suggesting a pathogenic (immune-mediated) mechanism of atherosclerosis development ( Garshick et al., 2019).